ID   I23O2_HUMAN             Reviewed;         420 AA.
AC   Q6ZQW0; A4UD41; F5H5G0;
DT   01-MAY-2007, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2015, sequence version 4.
DT   10-MAY-2017, entry version 100.
DE   RecName: Full=Indoleamine 2,3-dioxygenase 2;
DE            Short=IDO-2;
DE            EC=1.13.11.- {ECO:0000269|PubMed:17671174};
DE   AltName: Full=Indoleamine 2,3-dioxygenase-like protein 1;
DE   AltName: Full=Indoleamine-pyrrole 2,3-dioxygenase-like protein 1;
GN   Name=IDO2; Synonyms=INDOL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 13-420 (ISOFORM 1).
RX   PubMed=17499941; DOI=10.1016/j.gene.2007.04.010;
RA   Ball H.J., Sanchez-Perez A., Weiser S., Austin C.J.D., Astelbauer F.,
RA   Miu J., McQuillan J.A., Stocker R., Jermiin L.S., Hunt N.H.;
RT   "Characterization of an indoleamine 2,3-dioxygenase-like protein found
RT   in humans and mice.";
RL   Gene 396:203-213(2007).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, ALTERNATIVE SPLICING, ENZYME REGULATION,
RP   TISSUE SPECIFICITY, AND VARIANTS TRP-248 AND 359-TYR--GLY-420 DEL.
RX   PubMed=17671174; DOI=10.1158/0008-5472.CAN-07-1872;
RA   Metz R., Duhadaway J.B., Kamasani U., Laury-Kleintop L., Muller A.J.,
RA   Prendergast G.C.;
RT   "Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical
RT   target of the antitumor indoleamine 2,3-dioxygenase inhibitory
RT   compound D-1-methyl-tryptophan.";
RL   Cancer Res. 67:7082-7087(2007).
RN   [6]
RP   MISCELLANEOUS, AND DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=18418598; DOI=10.1007/s00262-008-0513-6;
RA   Loeb S., Koenigsrainer A., Zieker D., Bruecher B.L., Rammensee H.G.,
RA   Opelz G., Terness P.;
RT   "IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-
RT   methyl tryptophan inhibits tryptophan catabolism.";
RL   Cancer Immunol. Immunother. 58:153-157(2009).
RN   [7]
RP   POLYMORPHISM, AND DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=25394548; DOI=10.1038/emm.2014.69;
RA   Lee Y.K., Lee H.B., Shin D.M., Kang M.J., Yi E.C., Noh S., Lee J.,
RA   Lee C., Min C.K., Choi E.Y.;
RT   "Heme-binding-mediated negative regulation of the tryptophan metabolic
RT   enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2.";
RL   Exp. Mol. Med. 46:E121-E121(2014).
RN   [8]
RP   DIFFERENCE BETWEEN IDO1 AND IDO2.
RX   PubMed=25950090; DOI=10.1111/febs.13316;
RA   Yuasa H.J., Mizuno K., Ball H.J.;
RT   "Low efficiency IDO2 enzymes are conserved in lower vertebrates,
RT   whereas higher efficiency IDO1 enzymes are dispensable.";
RL   FEBS J. 282:2735-2745(2015).
RN   [9]
RP   REVIEW.
RX   PubMed=25477879; DOI=10.3389/fimmu.2014.00585;
RA   Prendergast G.C., Metz R., Muller A.J., Merlo L.M., Mandik-Nayak L.;
RT   "IDO2 in immunomodulation and autoimmune disease.";
RL   Front. Immunol. 5:585-585(2014).
RN   [10]
RP   REVIEW, AND TISSUE SPECIFICITY.
RX   PubMed=25691885; DOI=10.3389/fimmu.2015.00034;
RA   van Baren N., Van den Eynde B.J.;
RT   "Tryptophan-degrading enzymes in tumoral immune resistance.";
RL   Front. Immunol. 6:34-34(2015).
CC   -!- FUNCTION: Catalyzes the first and rate limiting step of the
CC       catabolism of the essential amino acid tryptophan along the
CC       kynurenine pathway (PubMed:17671174). Involved in immune
CC       regulation. May not play a significant role in tryptophan-related
CC       tumoral resistance (PubMed:25691885).
CC       {ECO:0000269|PubMed:17671174, ECO:0000303|PubMed:25691885}.
CC   -!- CATALYTIC ACTIVITY: L-tryptophan + O(2) = N-formyl-L-kynurenine.
CC       {ECO:0000269|PubMed:17671174}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:P14902};
CC       Note=Binds 1 heme group per subunit.
CC       {ECO:0000250|UniProtKB:P14902};
CC   -!- ENZYME REGULATION: Activity is inhibited by D-1MT (1-methyl-D-
CC       tryptophan) and MTH-trp (methylthiohydantoin-DL-tryptophan) but
CC       not L-1MT (1-methyl-L-tryptophan). {ECO:0000269|PubMed:17671174}.
CC   -!- PATHWAY: Amino-acid degradation; L-tryptophan degradation via
CC       kynurenine pathway; L-kynurenine from L-tryptophan: step 1/2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms exist at least in placenta and
CC         brain. {ECO:0000269|PubMed:17671174,
CC         ECO:0000303|PubMed:25477879};
CC       Name=1;
CC         IsoId=Q6ZQW0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6ZQW0-2; Sequence=VSP_024858, VSP_024859;
CC   -!- TISSUE SPECIFICITY: Detected in liver, small intestine, spleen,
CC       placenta, thymus, lung, brain, kidney, and colon
CC       (PubMed:17671174). Also expressed at low level in testis and
CC       thyroid. Not expressed in the majority of human tumor samples
CC       (>99%) (PubMed:25691885). {ECO:0000269|PubMed:17671174,
CC       ECO:0000303|PubMed:25691885}.
CC   -!- POLYMORPHISM: The variant Trp-248 (p.R248W) drastically reduces
CC       the enzymatic activity (PubMed:17671174, PubMed:18418598). The
CC       Del359-420 variant (p.Y359X) generates a truncated, enzymatically
CC       inactive protein (PubMed:17671174). The high prevalence of these
CC       polymorphic alleles results in a non-functional IDO2 enzyme in up
CC       to 50% of Caucasians (PubMed:18418598).
CC       {ECO:0000269|PubMed:17671174, ECO:0000303|PubMed:18418598}.
CC   -!- MISCELLANEOUS: IDO1 and IDO2 are 2 distinct enzymes which catalyze
CC       the same reaction. IDO2 affinity for tryptophan is much lower than
CC       that of IDO1. 50 % of Caucasians harbor polymorphisms which
CC       abolish IDO2 enzymatic activity. IDO2 is expressed in human tumors
CC       in an inactive form: tryptophan degradation is entirely provided
CC       by IDO1 in these cells (PubMed:18418598). IDO2 may play a role as
CC       a negative regulator of IDO1 by competing for heme-binding with
CC       IDO1 (PubMed:25394548). Low efficiency IDO2 enzymes have been
CC       conserved throughout vertebrate evolution, whereas higher
CC       efficiency IDO1 enzymes are dispensable in many lower vertebrate
CC       lineages (PubMed:25950090). IDO1 may have arisen by gene
CC       duplication of a more ancient proto-IDO gene before the divergence
CC       of marsupial and eutherian (placental) mammals.
CC       {ECO:0000269|PubMed:18418598, ECO:0000269|PubMed:25394548,
CC       ECO:0000269|PubMed:25950090}.
CC   -!- SIMILARITY: Belongs to the indoleamine 2,3-dioxygenase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IDO2ID44387ch8p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; EF052681; ABM69260.1; -; mRNA.
DR   EMBL; AK128691; BAC87573.1; -; mRNA.
DR   EMBL; AC007991; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087518; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113496; AAI13497.1; -; mRNA.
DR   EMBL; BC113498; AAI13499.1; -; mRNA.
DR   CCDS; CCDS6114.2; -. [Q6ZQW0-1]
DR   RefSeq; NP_919270.2; NM_194294.2. [Q6ZQW0-1]
DR   UniGene; Hs.676257; -.
DR   ProteinModelPortal; Q6ZQW0; -.
DR   SMR; Q6ZQW0; -.
DR   BioGrid; 127980; 9.
DR   IntAct; Q6ZQW0; 2.
DR   STRING; 9606.ENSP00000443432; -.
DR   BindingDB; Q6ZQW0; -.
DR   ChEMBL; CHEMBL3627587; -.
DR   iPTMnet; Q6ZQW0; -.
DR   PhosphoSitePlus; Q6ZQW0; -.
DR   BioMuta; IDO2; -.
DR   DMDM; 215274147; -.
DR   PaxDb; Q6ZQW0; -.
DR   PeptideAtlas; Q6ZQW0; -.
DR   PRIDE; Q6ZQW0; -.
DR   DNASU; 169355; -.
DR   Ensembl; ENST00000502986; ENSP00000443432; ENSG00000188676. [Q6ZQW0-1]
DR   GeneID; 169355; -.
DR   KEGG; hsa:169355; -.
DR   UCSC; uc010lwy.1; human.
DR   UCSC; uc064mgi.1; human. [Q6ZQW0-1]
DR   CTD; 169355; -.
DR   DisGeNET; 169355; -.
DR   GeneCards; IDO2; -.
DR   H-InvDB; HIX0007468; -.
DR   HGNC; HGNC:27269; IDO2.
DR   MIM; 612129; gene.
DR   neXtProt; NX_Q6ZQW0; -.
DR   OpenTargets; ENSG00000188676; -.
DR   PharmGKB; PA164720782; -.
DR   eggNOG; ENOG410IGEY; Eukaryota.
DR   eggNOG; ENOG410XQHE; LUCA.
DR   GeneTree; ENSGT00390000002154; -.
DR   HOGENOM; HOG000190192; -.
DR   InParanoid; Q6ZQW0; -.
DR   KO; K00463; -.
DR   OMA; PAGLMYE; -.
DR   OrthoDB; EOG091G0DCU; -.
DR   PhylomeDB; Q6ZQW0; -.
DR   TreeFam; TF330978; -.
DR   BRENDA; 1.13.11.52; 2681.
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   UniPathway; UPA00333; UER00453.
DR   ChiTaRS; IDO2; human.
DR   GenomeRNAi; 169355; -.
DR   PRO; PR:Q6ZQW0; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000188676; -.
DR   ExpressionAtlas; Q6ZQW0; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0033754; F:indoleamine 2,3-dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004833; F:tryptophan 2,3-dioxygenase activity; EXP:Reactome.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0006569; P:tryptophan catabolic process; TAS:Reactome.
DR   GO; GO:0019441; P:tryptophan catabolic process to kynurenine; IDA:UniProtKB.
DR   InterPro; IPR000898; Indolamine_dOase.
DR   Pfam; PF01231; IDO; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Dioxygenase; Heme; Immunity;
KW   Iron; Metal-binding; Oxidoreductase; Polymorphism; Reference proteome;
KW   Tryptophan catabolism.
FT   CHAIN         1    420       Indoleamine 2,3-dioxygenase 2.
FT                                /FTId=PRO_0000285262.
FT   METAL       360    360       Iron (heme proximal ligand).
FT                                {ECO:0000250|UniProtKB:P14902}.
FT   VAR_SEQ     159    172       FLEIGNLETIISFP -> DGVSLCLPGWSAVA (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_024858.
FT   VAR_SEQ     173    420       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_024859.
FT   VARIANT     248    248       R -> W (decreased indoleamine 2,3-
FT                                dioxygenase activity; dbSNP:rs10109853).
FT                                {ECO:0000269|PubMed:17671174}.
FT                                /FTId=VAR_032007.
FT   VARIANT     359    420       Missing (loss of indoleamine 2,3-
FT                                dioxygenase activity).
FT                                {ECO:0000269|PubMed:17671174}.
FT                                /FTId=VAR_073727.
FT   CONFLICT      1     13       Missing (in Ref. 1; ABM69260).
FT                                {ECO:0000305}.
SQ   SEQUENCE   420 AA;  47075 MW;  28C0CDCD10F933C4 CRC64;
     MLHFHYYDTS NKIMEPHRPN VKTAVPLSLE SYHISEEYGF LLPDSLKELP DHYRPWMEIA
     NKLPQLIDAH QLQAHVDKMP LLSCQFLKGH REQRLAHLVL SFLTMGYVWQ EGEAQPAEVL
     PRNLALPFVE VSRNLGLPPI LVHSDLVLTN WTKKDPDGFL EIGNLETIIS FPGGESLHGF
     ILVTALVEKE AVPGIKALVQ ATNAILQPNQ EALLQALQRL RLSIQDITKT LGQMHDYVDP
     DIFYAGIRIF LSGWKDNPAM PAGLMYEGVS QEPLKYSGGS AAQSTVLHAF DEFLGIRHSK
     ESGDFLYRMR DYMPPSHKAF IEDIHSAPSL RDYILSSGQD HLLTAYNQCV QALAELRSYH
     ITMVTKYLIT AAAKAKHGKP NHLPGPPQAL KDRGTGGTAV MSFLKSVRDK TLESILHPRG
//
